Boehringer Ingelheim gets interim injunction against Dr. Reddy’s Labs, MSN Labs against copies of anti-diabetes drug

In a statement to ET, BI confirmed it has obtained separate orders granting ad-interim injunction that restrains the two domestic pharmaceutical manufacturers from launching, making, using, offering for sale, selling, importing and/or exporting their respective generic version of empagliflozin drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3jD92me
via IFTTT